Welcome to the 5th TPD & Induced Proximity Summit Europe
Accelerating PROTAC’s, Glues & Novel Non-Degrading TACs to Patients Faster
Induced proximity medicines are revolutionising therapeutic strategies, offering groundbreaking solutions for disease treatment.
In 2024 alone, PhoreMost secured $50 million in Series B financing for its degrader programs, while Merck KGaA partnered with C4 Therapeutics in a $756 million deal focused on protein degraders.
However, challenges remain in making PROTACs orally bioavailable, effectively discovering molecular glues, and developing non-degrading proximity therapeutics.
Join the The 5th TPD Summit Europe to network with over 100 experts and learn about the latest advancements in degraders (PROTACs, lysosomal, surface, and ECM), molecular glues, and non-degrading proximity therapeutics. Accelerate your research and bring innovative therapies to patients faster.
ACCESS THE FULL PROGRAM
Explore the brochure to see the exciting insights in store for you and more!
Sessions You Can't Miss:
Top Speakers:
Attending Companies Include:
Testimonials:
Other Events in the Small Molecules & TPD World Series:
